Sidoti Csr Analysts Boost Earnings Estimates for Balchem Co. (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Analysts at Sidoti Csr lifted their Q2 2024 EPS estimates for shares of Balchem in a report issued on Monday, May 6th. Sidoti Csr analyst K. May now anticipates that the basic materials company will post earnings of $1.06 per share for the quarter, up from their previous forecast of $1.00. The consensus estimate for Balchem’s current full-year earnings is $4.10 per share. Sidoti Csr also issued estimates for Balchem’s FY2025 earnings at $4.13 EPS.

A number of other research firms have also weighed in on BCPC. StockNews.com lowered shares of Balchem from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. HC Wainwright lifted their price objective on shares of Balchem from $167.00 to $170.00 and gave the company a “buy” rating in a research report on Monday.

Balchem Stock Down 1.4 %

Shares of NASDAQ:BCPC opened at $153.28 on Thursday. The company has a quick ratio of 1.72, a current ratio of 2.61 and a debt-to-equity ratio of 0.31. The stock has a market cap of $4.97 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 3.33 and a beta of 0.72. The firm’s 50 day moving average price is $150.98 and its 200 day moving average price is $141.30. Balchem has a fifty-two week low of $110.74 and a fifty-two week high of $159.52.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.02. The business had revenue of $228.70 million for the quarter, compared to analysts’ expectations of $234.66 million. Balchem had a net margin of 12.35% and a return on equity of 11.03%. The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.66 earnings per share.

Insider Transactions at Balchem

In related news, CAO William A. Backus sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $154.73, for a total transaction of $2,320,950.00. Following the transaction, the chief accounting officer now directly owns 12,914 shares of the company’s stock, valued at approximately $1,998,183.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CAO William A. Backus sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $154.73, for a total transaction of $2,320,950.00. Following the completion of the transaction, the chief accounting officer now owns 12,914 shares of the company’s stock, valued at $1,998,183.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO William A. Backus sold 9,180 shares of the company’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $156.37, for a total value of $1,435,476.60. Following the transaction, the chief accounting officer now directly owns 12,914 shares in the company, valued at $2,019,362.18. The disclosure for this sale can be found here. In the last quarter, insiders sold 76,630 shares of company stock worth $11,843,249. 1.77% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Balchem

A number of hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its holdings in shares of Balchem by 18.0% during the first quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock worth $73,000 after buying an additional 72 shares in the last quarter. Cardinal Capital Management increased its stake in Balchem by 0.4% during the 4th quarter. Cardinal Capital Management now owns 19,539 shares of the basic materials company’s stock worth $2,922,000 after acquiring an additional 79 shares during the period. Signaturefd LLC increased its stake in Balchem by 123.0% during the 4th quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock worth $25,000 after acquiring an additional 91 shares during the period. SageView Advisory Group LLC increased its stake in shares of Balchem by 2.1% in the 3rd quarter. SageView Advisory Group LLC now owns 4,814 shares of the basic materials company’s stock valued at $597,000 after purchasing an additional 98 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in Balchem by 0.7% in the third quarter. Commonwealth Equity Services LLC now owns 14,532 shares of the basic materials company’s stock valued at $1,803,000 after buying an additional 104 shares in the last quarter. Institutional investors own 87.91% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.